Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: Revisiting the evidence for risk reduction

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Heemskerk Gerritsen, B A M ^a   Seynaeve, C ^a   Van Asperen, C J ^b   Ausems, M G E M ^c   Collee J M ^a   Van Doorn, H C ^a   Gomez Garcia, E B ^d   Kets, C M ^e   Van Leeuwen, F E ^f   Meijers Heijboer, H E J ^g,h   Mourits, M J E ⁱ   Van Os, T A M ^h   Vasen, H F A ^j   Verhoef, S ^f   Rookus, M A ^f   Hooning, M J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h ACADEMIC MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^j Netherlands Foundation for Detection of Hereditary Tumours   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE MUTATION; HAZARD RATIO; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK REDUCTION; SALPINGOOOPHORECTOMY; AGED; BREAST NEOPLASMS; CHEMISTRY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HETEROZYGOTE; INCIDENCE; MIDDLE AGED; MUTATION; NETHERLANDS; NUCLEOTIDE SEQUENCE; OVARIECTOMY; RISK; RISK ASSESSMENT; RISK FACTOR; SALPINGECTOMY; TIME;

AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HETEROZYGOTE; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; NETHERLANDS; ODDS RATIO; OVARIECTOMY; PROPORTIONAL HAZARDS MODELS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; SALPINGECTOMY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84928421635     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv033     Document Type: Article

References (31)

1. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Human Gen. 1998;62:676-689.
2. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New Engl J Med. 1997;336(20):1401-1408.
3. Bergfeldt K, Rydh B, Granath F, et al. Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: A populationbased cohort study. Lancet. 2002;360(9337):891-894.
4. King MC, Marks JH, Mandell JB, Grp NYBCS. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646.
5. Metcalfe K, Lynch HT, Chadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-2335.
6. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2003;21(9):1675-1681.
7. Bradbury AR, Ibe CN, Dignam JJ, et al. Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genet Med. 2008;10(3):161-166.
8. Evans DGR, Lalloo F, Ashcroft L, et al. Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. Cancer Epidem Biomar. 2009;18(8):2318-2324.
9. Beattie M, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biom. 2009;13(1):51-56.
10. Skytte AB, Gerdes AM, Andersen MK, et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet. 2010;77(4):342-349.
11. Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132(2):428-433.
12. Meeuwissen PAM, Seynaeve C, Brekelmans CTM, et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97(2):476-482.
13. Hermsen BBJ, Olivier RI, Verheijen RHM, et al. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer. 2007;96(9):1335-1342.
14. Evans DG, Gaarenstroom KN, Stirling D, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009;46(9):593-597.
15. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80-87.
16. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst. 1999;91(17):1475-1479.
17. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-1622.
18. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol. 2005;23:7491-7496.
19. Kramer JL, Velazquez IA, Chen BSE, et al. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005;23(34):8629-8635.
20. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol. 2006;7(3):223-229.
21. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol. 2008;26(8):1331-1337.
22. Domchek SM, Friebel TM, Singer CF, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. J Am Med Assoc. 2010;304(9):967-975.
23. Kurian AW, Munoz DF, Rust P, et al. Online Tool to Guide Decisions for BRCA1/2 Mutation Carriers. J Clin Oncol. 2012;30(5):497-506.
24. Klaren HM, van 't Veer LJ, van Leeuwen FE, Rookus MA. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst. 2003;95(13):941-947.
25. Wacholder S. Bias in Intervention Studies That Enroll Patients From High-Risk Clinics. J Natl Cancer Inst. 2004;96(16):1204-1207.
26. Pijpe A, Manders P, Brohet RM, et al. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat. 2010;120(1):235-244.
27. Simon R, Makuch RW. A Non-Parametric Graphical Representation of the Relationship between Survival and the Occurrence of an Event-Application to Responder Versus Non-Responder Bias. Stat Med. 1984;3(1):35-44.
28. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Meth Psych Res. 2002;11(2):68-74.
29. Hussein MR, Abd-Elwahed SRAH, Abdulwahed AR. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Biol Int. 2008;32(6):698-707.
30. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res. 1998;58(15):3197-3201.
31. Loman N, Johannsson O, Bendahl PO, et al. Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes. Cancer. 1998;83(2):310-319.